Immuron Ltd has released a press release.
US DoD Receives FDA Guidance on clinical development plans
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- IMC & CSIRO to produce oral therapeutic for DoD evaluation
- Response to ASX Price Query
- Immuron Global Sales Up 60%
- Resignation of Managing Director and cuts amid Covid19
- North American Travelan sales up 98% to Dec 2019
Later from Immuron
- Immuron Reports Neutralizing activity Against SARS-CoV-2
- Immuron Announces US$20.0 Million Registered Direct Offering
- Appendix 4E and 2020 Financial Report
- Immuron Travelers Diarrhea Market Update
- US DoD NMRC Reports Positive Response to Vaccine
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron